標(biāo)題: Titlebook: Gapmers; Methods and Protocol Toshifumi Yokota,Rika Maruyama Book 2020 Springer Science+Business Media, LLC, part of Springer Nature 2020 A [打印本頁] 作者: 氣泡 時(shí)間: 2025-3-21 19:49
書目名稱Gapmers影響因子(影響力)
書目名稱Gapmers影響因子(影響力)學(xué)科排名
書目名稱Gapmers網(wǎng)絡(luò)公開度
書目名稱Gapmers網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Gapmers被引頻次
書目名稱Gapmers被引頻次學(xué)科排名
書目名稱Gapmers年度引用
書目名稱Gapmers年度引用學(xué)科排名
書目名稱Gapmers讀者反饋
書目名稱Gapmers讀者反饋學(xué)科排名
作者: 稀釋前 時(shí)間: 2025-3-21 22:59
Gapmers978-1-0716-0771-8Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: coagulate 時(shí)間: 2025-3-22 02:32 作者: mendacity 時(shí)間: 2025-3-22 05:30 作者: exophthalmos 時(shí)間: 2025-3-22 10:05
Piero Filipponi,Alwyn F. Horadamtudy estimates that at least four times more lncRNAs are typically present than coding RNAs in humans. However, function of more than 95% of human lncRNAs are still unknown. Synthetic antisense oligonucleotides called gapmers are powerful tools for lncRNA loss-of-function studies. Gapmers contain a 作者: MEET 時(shí)間: 2025-3-22 15:36
Some Notes on Fibonacci Binary Sequences,ogenicity, thereby providing considerable insight to develop suitable therapies. With the successful translation of antisense oligonucleotides (AOs) from in vitro into animal models and clinical practice, modifications are being continuously made to the AOs to improve the pharmacokinetics and pharma作者: MEET 時(shí)間: 2025-3-22 18:56 作者: miscreant 時(shí)間: 2025-3-22 21:41 作者: CHASM 時(shí)間: 2025-3-23 04:59
Computing with the Unpredictablef repeat sequences in the . and . genes, respectively. The expansions are highly unstable and biased for further expansion in somatic cells and across generations. Despite the different genes involved, DM1 and DM2 share several clinical features due to having the similar underlying mechanism of repe作者: 墊子 時(shí)間: 2025-3-23 05:55
Interdisciplinary Systems ResearchRNA (cRNA) strand. HDOs were originally designed to improve the properties of RNase H-dependent ASOs and we reported in our first paper that HDOs conjugated with an α-tocopherol ligand (Toc-HDO) based on a gapmer ASO showed 20 times higher silencing effect to liver apolipoprotein B (apoB) mRNA in vi作者: 主動(dòng)脈 時(shí)間: 2025-3-23 13:00 作者: 東西 時(shí)間: 2025-3-23 13:55
Luella Marcos,Paul Babyn,Javad Alirezaieing is the lack of appropriate in vitro validation systems that can predict in vivo activity and toxicity. We have devised a transfection method called CEM (Ca.-enrichment method), where the simple enrichment of calcium ion with calcium chloride in culture medium potentiates the activity of various 作者: 仔細(xì)閱讀 時(shí)間: 2025-3-23 22:05
Breeding for Disease Resistancetherapeutic purposes. For in vitro evaluation of the knockdown activity of gapmer ASOs, we often use lipofection or electroporation to deliver gapmer ASOs into the cells. Here, we describe a method for evaluating the knockdown activity of gapmer ASOs by a cell-free uptake mechanism, termed as gymnos作者: 助記 時(shí)間: 2025-3-23 23:18 作者: 送秋波 時(shí)間: 2025-3-24 05:50
Jumpei Tsujiuchi,George W. Strokeisease appears to manifest sporadically. The recent discovery of the hexanucleotide repeat expansion in the C9orf72 gene as the causative agent of ALS (C9ALS) gives rise to the opportunity to develop new therapies directed at this mutation, which is responsible for a large proportion of ALS and/or f作者: –scent 時(shí)間: 2025-3-24 07:44 作者: 恩惠 時(shí)間: 2025-3-24 13:05 作者: 宴會(huì) 時(shí)間: 2025-3-24 18:49 作者: Soliloquy 時(shí)間: 2025-3-24 20:22 作者: 審問 時(shí)間: 2025-3-25 02:32
Toshifumi Yokota,Rika MaruyamaIncludes cutting-edge methods and protocols.Provides step-by-step detail essential for reproducible results.Contains key notes and implementation advice from the experts作者: Talkative 時(shí)間: 2025-3-25 06:50 作者: 珍奇 時(shí)間: 2025-3-25 08:21
1064-3745 tocols, and tips on troubleshooting and avoiding known pitfalls...?Authoritative and cutting-edge, .Gapmers: Methods and Protocols. aims to provide diverse applications of gapmers along with protocols that will assist readers in moving the frontier..978-1-0716-0773-2978-1-0716-0771-8Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: 松雞 時(shí)間: 2025-3-25 13:44 作者: 不可知論 時(shí)間: 2025-3-25 17:50 作者: Innocence 時(shí)間: 2025-3-25 20:57
https://doi.org/10.1007/978-94-009-0223-7that have a PS backbone flanked with the modified AOs on both sides. Mipomersen (trade name Kynamro), a 2′-.-methoxyethyl (MOE) gapmer, was approved by the Food and Drug Administration (FDA) for the treatment of homozygous familial hypercholesterolemia (HoFH) in 2013. Volanesorsen, another 20-mer MO作者: ABHOR 時(shí)間: 2025-3-26 02:55 作者: 盡忠 時(shí)間: 2025-3-26 07:08
Computing with the Unpredictable RNase H cleavage while having enhanced target binding affinity and nuclease resistance. This chapter will consolidate the different strategies studied thus far to develop a treatment for DM1 through the targeting of toxic repetitive RNA using gapmers.作者: 凹處 時(shí)間: 2025-3-26 11:59
Geometric and Algebraic Canonical Formsothioate or phosphodiester backbone modifications. This work offers a strategy to optimize gapmer ASO pharmacokinetics by a proposed endogenous assembly process with serum albumin that can be tuned by gapmer ASO design modifications.作者: –FER 時(shí)間: 2025-3-26 13:32
Jumpei Tsujiuchi,George W. Strokef72 repeat expanded transcripts resulted in recovery from the disease-related phenotypes in patient-derived fibroblasts. Our findings highlight the therapeutic potential of C9ALS using this gapmer oligonucleotide-based approach.作者: doxazosin 時(shí)間: 2025-3-26 17:26 作者: 極深 時(shí)間: 2025-3-27 01:02 作者: 擴(kuò)張 時(shí)間: 2025-3-27 02:40
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophythat have a PS backbone flanked with the modified AOs on both sides. Mipomersen (trade name Kynamro), a 2′-.-methoxyethyl (MOE) gapmer, was approved by the Food and Drug Administration (FDA) for the treatment of homozygous familial hypercholesterolemia (HoFH) in 2013. Volanesorsen, another 20-mer MO作者: 帶來墨水 時(shí)間: 2025-3-27 07:22
Inotersen for the Treatment of Hereditary Transthyretin Amyloidosiss of the liver cells. By doing so, it prevents the production of the mutant and wild-type forms of transthyretin, impeding the progression of the disease. In this article, the mechanism of action and safety profile of inotersen will be discussed along with some future directions following its approv作者: separate 時(shí)間: 2025-3-27 12:34 作者: misshapen 時(shí)間: 2025-3-27 15:50
Albumin-Binding Fatty Acid–Modified Gapmer Antisense Oligonucleotides for Modulation of Pharmacokineothioate or phosphodiester backbone modifications. This work offers a strategy to optimize gapmer ASO pharmacokinetics by a proposed endogenous assembly process with serum albumin that can be tuned by gapmer ASO design modifications.作者: 禮節(jié) 時(shí)間: 2025-3-27 21:34 作者: CHAFE 時(shí)間: 2025-3-27 23:13
Invention and Early History of Gapmers sequence complementarity, gapmers recruit ribonuclease H and induce target RNA degradation. Since its concept first emerged in the 1980s, much work has gone into developing gapmers for use in basic research and therapy. These include improvements in gapmer chemistry, delivery, and therapeutic safet作者: 評論性 時(shí)間: 2025-3-28 04:48 作者: 案發(fā)地點(diǎn) 時(shí)間: 2025-3-28 08:39 作者: follicular-unit 時(shí)間: 2025-3-28 12:31
Development of Antisense Oligonucleotide Gapmers for the Treatment of Huntington’s Diseaseogenicity, thereby providing considerable insight to develop suitable therapies. With the successful translation of antisense oligonucleotides (AOs) from in vitro into animal models and clinical practice, modifications are being continuously made to the AOs to improve the pharmacokinetics and pharma作者: 枕墊 時(shí)間: 2025-3-28 15:41
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy diseases, the translation of the genetic mechanisms into a clinical setting has been quite challenging, with a minimum number of effective treatments available. The advancements in antisense therapy have revolutionized the field of neuromuscular disorders as well as lipid-mediated diseases. With th作者: 大方不好 時(shí)間: 2025-3-28 19:00 作者: 難解 時(shí)間: 2025-3-29 01:23
Degradation of Toxic RNA in Myotonic Dystrophy Using Gapmer Antisense Oligonucleotidesf repeat sequences in the . and . genes, respectively. The expansions are highly unstable and biased for further expansion in somatic cells and across generations. Despite the different genes involved, DM1 and DM2 share several clinical features due to having the similar underlying mechanism of repe作者: 軟弱 時(shí)間: 2025-3-29 04:23 作者: textile 時(shí)間: 2025-3-29 09:27 作者: 即席 時(shí)間: 2025-3-29 14:40
Calcium-Mediated In Vitro Transfection Technique of Oligonucleotides with Broad Chemical Modificatioing is the lack of appropriate in vitro validation systems that can predict in vivo activity and toxicity. We have devised a transfection method called CEM (Ca.-enrichment method), where the simple enrichment of calcium ion with calcium chloride in culture medium potentiates the activity of various 作者: Patrimony 時(shí)間: 2025-3-29 19:27
Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitrotherapeutic purposes. For in vitro evaluation of the knockdown activity of gapmer ASOs, we often use lipofection or electroporation to deliver gapmer ASOs into the cells. Here, we describe a method for evaluating the knockdown activity of gapmer ASOs by a cell-free uptake mechanism, termed as gymnos作者: 揭穿真相 時(shí)間: 2025-3-29 19:53 作者: Type-1-Diabetes 時(shí)間: 2025-3-30 00:38
Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/FTD Caused by the C9orf72 Repeat Expisease appears to manifest sporadically. The recent discovery of the hexanucleotide repeat expansion in the C9orf72 gene as the causative agent of ALS (C9ALS) gives rise to the opportunity to develop new therapies directed at this mutation, which is responsible for a large proportion of ALS and/or f作者: BUOY 時(shí)間: 2025-3-30 06:04 作者: 上下連貫 時(shí)間: 2025-3-30 11:45 作者: –LOUS 時(shí)間: 2025-3-30 16:14
A Generalization of the Fibonacci Search,ation for the treatment of familial hypercholesterolemia and transthyretin amyloidosis-associated polyneuropathy. Here, we review the events surrounding the early development of gapmers, from conception to their maturity, and briefly conclude with perspectives on their use in therapy.作者: 過分 時(shí)間: 2025-3-30 17:48 作者: grounded 時(shí)間: 2025-3-30 21:58 作者: 存心 時(shí)間: 2025-3-31 03:40
Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitrouse it does not involve the use of any transfection reagent and has minimal effects on cell growth. Further, we describe a convenient technique for performing one-step reverse transcription and real-time qPCR using cell lysates without RNA extraction. Data for up to 96 samples can be obtained following these methods.作者: 使熄滅 時(shí)間: 2025-3-31 05:52
Interdisciplinary Systems Researchvo than the parent ASO. Thereafter the HDO strategy was found to be also effective for improving the properties of ASOs modulating blood–brain barrier function and ASO antimiRs which are RNase H-independent ASOs. Therefore, the HDO strategy has been shown to be versatile technology platform to develop effective nucleic acid drugs.作者: Peak-Bone-Mass 時(shí)間: 2025-3-31 12:38
Piergiulio Corsini,Violeta Leoreanued. The methods comprise the design of gapmer ASOs and the in vitro evaluation of gapmer ASOs on the specific silencing of the mutant allele at mRNA levels, and functional assessment at protein levels. A fibroblast cell line cultured from a UCMD patient carrying a dominant mutation in one of the . genes is used as a cellular model.作者: 過時(shí) 時(shí)間: 2025-3-31 15:01
